A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of Single Dose of AMG 623 in Subjects With Systemic Lupus Erythematosus

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2004
This study is to evaluate the safety of AMG 623 in subjects with systemic lupus erythematosus. The study consists of a 21 day screening period followed by administration of the investigational product and up to 70 day follow up period.
Epistemonikos ID: 6c0857b56f1e66c9958826c75c49421046988a1a
First added on: May 12, 2024